ADSL and tuberculosis: This approach attain key objectives such as protection against proteolysis and renal clearance—as encapsulation or conjugation protects peptides from enzymatic degradation and prolongs circulation time—targeted delivery to intracellular reservoirs—as size optimization, surface functionalization and inhalation routes allow specific action on alveolar macrophages and granulomas [217,219]—and the potential use in combination therapy—as co-loading of AMPs with conventional anti-TB drugs allows for synergistic effects and reduces required dosages [218,221].